Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C

CORK, Ireland--(BUSINESS WIRE)--Results from the Phase 2 COSMOS (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with Janssen R&D Ireland’s (Janssen) simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir, achieved sustained virologic response 12 weeks after the end of treatment (SVR12), including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon (PegIFN) and ribavirin (RBV).

Help employers find you! Check out all the jobs and post your resume.